Chronic mye-logenous leukemia (CML) has long been recognized as an entity responsive to immunotherapeutic interventions. Despite the success of the tyrosine kinase inhibitors (TKIs) in this disease, CML remains incurable. Only allogeneic bone marrow transplantation can provide long-term eradication of CML.
Methods
This review summarizes the recent advances in the field of immunology in CML, specifically in tumor antigen discovery, that have been incorporated into the design of new clinical trials.
Results
Multiple vaccine approaches are currently under clinical investigation. Recent laboratory and clinical data also point to a unique interaction of TKIs with the immune system.
Conclusions
A better understanding of these interactions combined with advances in the field of immunotherapy will likely lead to incorporation of TKIs in future therapeutic interventions to develop a cure for this disease.
References
1.
AntinJ.H.. Graft-versus-leukemia: no longer an epiphenomenon.Blood.1993; 82(8): 2273–2277.
2.
RezvaniK., BarrettA.J.. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.Best Pract Res Clin Haematol.2008; 21(3): 437–453.
3.
RezvaniK., YongA.S., SavaniB.N.. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allo-geneic stem-cell transplantation for acute lymphoblastic leukemia.Blood.2007; 110(6): 1924–1932. Epub 2007 May 15.
4.
SmitW.M., RijnbeekM., van BergenC.A.. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.Proc Natl Acad Sci U S A.1998; 95(17): 10152–10157.
5.
FalkenburgJ.H., MarijtW.A., HeemskerkM.H.. Minor histocom-patibility antigens as targets of graft-versus-leukemia reactions.Curr Opin Hematol.2002; 9(6): 497–502.
6.
MarijtW.A., HeemskerkM.H., KloosterboerF.M.. Hematopoiesisrestricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.Proc Natl Acad Sci U S A.2003; 100(5): 2742–2747. Epub 2003 Feb 24.
7.
DrobyskiW.R., KeeverC.A., RothM.S.. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myeloge-nous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.Blood.1993; 82(8): 2310–2318.
8.
KolbH.J., MittermüllerJ., ClemmC.. Donor leukocyte transfusions for treatment of recurrent chronic mye-logenous leukemia in marrow transplant patients.Blood.1990; 76(12): 2462–2465.
9.
KolbH.J., SchattenbergA., GoldmanJ.M.. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.Blood.1995; 86(5): 2041–2050.
10.
van RheeF., LinF., CullisJ.O.. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.Blood.1994; 83(11): 3377–3383.
11.
de KleinA., van KesselA.G., GrosveldG.. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.Nature.1982; 300(5894): 765–767.
12.
HeisterkampN., StephensonJ.R., GroffenJ.. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocyt-ic leukaemia.Nature.1983; 306(5940): 239–242.
13.
RowleyJ.D.. Letter: A new consistent chromosomal abnormality in chronic mye-logenous leukemia, identified by quinacrine fluorescence and Giemsa staining.Nature.1973; 243(5405): 290–293.
14.
DeiningerM.W., GoldmanJ.M., MeloJ.V.. The molecular biology of chronic myeloid leukemia.Blood.2000; 96(10): 3343–3356.
15.
Ben-NeriahY., DaleyG.Q., Mes-MassonA.M.. The chronic mye-logenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.Science.1986; 233(4760): 212–214.
16.
ShtivelmanE., LifshitzB., GaleR.P.. Fused transcript of abl and bcr genes in chronic mye-logenous leukaemia.Nature.1985; 315(6020): 550–554.
17.
GrosveldG., VerwoerdT., van AgthovenT.. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.Mol Cell Biol.1986; 6(2): 607–616.
18.
KloetzerW., KurzrockR., SmithL.. The human cellular abl gene product in the chronic mye-logenous leukemia cell line K562 has an associated tyrosine protein kinase activity.Virology.1985; 140(2): 230–238.
19.
ShtivelmanE., LifshitzB., GaleR.P.. Alternative splicing of RNAs transcribed from the human abl gene and from the BCRABL fused gene.Cell.1986; 47(2): 277–284.
20.
BerkeZ., AndersenM.H., PedersenM.. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.Leukemia.2000; 14(3): 419–426.
21.
BocchiaM., KorontsvitT., XuQ.. Specific human cellular immunity to BCRABL oncogene-derived peptides.Blood.1996; 87(9): 3587–3592.
22.
BocchiaM., WentworthP.A., SouthwoodS.. Specific binding of leukemia oncogene fusion protein peptides to HLA classI molecules.Blood.1995; 85(10): 2680–2684.
23.
BuzynA., OstankovitchM., ZerbibA.. Peptides derived from the whole sequence of BCRABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.Eur J Immunol.1997; 27(8): 2066–2072.
24.
GrecoG., FruciD., AccapezzatoD.. Two BCRABL junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.Leukemia.1996; 10(4): 693–699.
25.
NiedaM., NicolA., KikuchiA.. Dendritic cells stimulate the expansion of BCRABL specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.Blood.1998; 91(3): 977–983.
26.
OsmanY., TakahashiM., ZhengZ.. Generation of BCRABL specific cytotoxic T-lymphocytes by using dendritic cells pulsed with BCRABL (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.Leukemia.1999; 13(2): 166–174.
27.
VolpeG., CignettiA., PanuzzoC.. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.Cancer Res.2007; 67(11): 5300–5307.
28.
WagnerW.M., OuyangQ., PawelecG.. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic mye-logenous leukemia.Leukemia.2002; 16(11): 2341–2343.
29.
WagnerW.M., OuyangQ., PawelecG.. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.Cancer Immunol Immunother.2003; 52(2): 89–96. Epub 2003 Jan 21.
30.
YotndaP., FiratH., Garcia-PonsF.. Cytotoxic T cell response against the chimeric p210 BCRABL protein in patients with chronic mye-logenous leukemia.J Clin Invest.1998; 101(10): 2290–2296.
31.
Pinilla-IbarzJ., CathcartK., ScheinbergD.A.. CML vaccines as a paradigm of the specific immunotherapy of cancer.Blood Rev.2000; 14(2): 111–120.
32.
ClarkR.E., DodiI.A., HillS.C.. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCRABL b3a2 fusion protein.Blood.2001; 98(10): 2887–2893.
33.
ButtN.M., RojasJ.M., WangL.. Circulating BCRABL–specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.Haematologica.2005; 90(10): 1315–1323.
34.
ClarkR.E., ChristmasS.E.. BCRABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.Leuk Lymphoma.2001; 42(5): 871–880.
35.
RezvaniK., GrubeM., BrenchleyJ.M.. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic mye-logenous leukemia before and after stem cell transplantation.Blood.2003; 102(8): 2892–2900. Epub 2003 Jun 26.
36.
ButtN.M., WangL., Abu-EishaH.M.. BCRABL–specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.Blood.2004; 103(8): 3245.
37.
MundhadaS., LuthraR., CanoP.. Association of HLA Class I and Class II genes with BCRABL transcripts in leukemia patients with t(9;22) (q34;q11).BMC Cancer.2004; 4: 25.
38.
PosthumaE.F., FalkenburgJ.H., ApperleyJ.F.. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.Leukemia.2000; 14(5): 859–862.
39.
PosthumaE.F., FalkenburgJ.H., ApperleyJ.F.. HLA-B8 and HLAA3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.Blood.1999; 93(11): 3863–3865.
40.
KesslerJ.H., Bres-VloemansS.A., van VeelenP.A.. BCRABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epi-topes.Leukemia.2006; 20(10): 1738–1750. Epub 2006 Aug 24.
41.
Pinilla-IbarzJ., KorontsvitT., ZakhalevaV.. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.Haematologica.2005; 90(10): 1324–1332.
42.
BocchiaM., KorontsvitT., XuQ.. Specific human cellular immunity to BCRABL oncogene-derived peptides.Blood.1996; 87(9): 3587–3592.
43.
PawelecG., MaxH., HalderT.. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.Blood.1996; 88(6): 2118–2124.
44.
ten BoschG.J., ToornvlietA.C., FriedeT.. Recognition of peptides corresponding to the joining region of p210BCRABL protein by human T cells.Leukemia.1995; 9(8): 1344–1348.
45.
BoschG.J., JoostenA.M., KesslerJ.H.. Recognition of BCRABL positive leukemic blast by human CD4+ T cells elicited by primary in vitro immunization with a BCRABL breakpoint peptide.Blood.1996; 88(9): 3522–3527.
46.
ManneringS.I., McKenzieJ.L., FearnleyD.B.. HLA-DR1-restricted BCRABL (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.Blood.1997; 90(1): 290–297.
47.
YasukawaM., OhminamiH., KanekoS.. CD4(+) cytotoxic T-cell clones specific for BCRABL b3a2 fusion peptide augment colony formation by chronic mye-logenous leukemia cells in a b3a2-specific and HLA-DR-restrict-ed manner.Blood.1998; 92(9): 3355–3361.
48.
ten BoschG.J., KesslerJ.H., JoostenA.M.. A BCRABL oncopro-tein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells trans-fected with an Ii(b2a2) construct.Blood.1999; 94(3): 1038–1045.
49.
MolldremJ.J., ClaveE., JiangY.Z.. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.Blood.1997; 90(7): 2529–2534.
50.
MolldremJ.J., DermimeS., ParkerK.. Targeted T cell therapy for human leukemia: cytotoxic lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.Blood.1996; 88(7): 2450–2457.
51.
OkaY., TsuboiA., ElisseevaO.A.. WT1 as a novel target antigen for cancer immunotherapy.Curr Cancer Drug Targets.2002; 2(1): 45–54.
52.
AriyaratanaS., LoebD.M.. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.Expert Rev Mol Med.2007; 9(14): 1–17.
OhminamiH., YasukawaM., FujitaS.. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.Blood.2000; 95(1): 286–293.
55.
AzumaT., MakitaM., NinomiyaK.. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes.Br J Haematol.2002; 116(3): 601–603.
56.
BellantuonoI., GaoL., ParryS.. Two distinct HLA-A0201-pre-sented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.Blood.2002; 100(10): 3835–3837.
57.
DoubrovinaE.S., DoubrovinM.M., LeeS.. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.Clin Cancer Res.2004; 10(21): 7207–7219.
58.
GaoL., BellantuonoI., ElsässerA.. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.Blood.2000; 95(7): 2198–2203.
59.
AsemissenA.M., KeilholzU., TenzerS.. Identification of a highly immunogenic HLA-A∗01-binding T cell epitope of WT1.Clin Cancer Res.2006; 12(24): 7476–7482.
60.
OkaY., ElisseevaO.A., TsuboiA.. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product.Immunogenetics.2000; 51(2): 99–107.
61.
LiZ., OkaY., TsuboiA.. WT1(235), a ninemer peptide derived from Wilms’ tumor gene product, is a candidate peptide for the vaccination of HLA-A∗0201-positive patients with hematopoietic malignancies.Int J Hematol.2005; 82(5): 458–459.
62.
ChaiseC., BuchanS.L., RiceJ.. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.Blood.2008; 112(7): 2956–2964. Epub 2008 May 23.
63.
NakajimaH., KawasakiK., OkaY.. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 pep-tide vaccination alone.Cancer Immunol Immunother.2004; 53(7): 617–624. Epub 2004 Feb 7.
64.
TsuboiA., OkaY., OgawaH.. Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination.J Clin Immunol.2000; 20(3): 195–202.
65.
GaoL., XueS.A., HasserjianR.. Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.Transplantation.2003; 75(9): 1429–1436.
66.
RezvaniK., BrenchleyJ.M., PriceD.A.. T-cell responses directed against multiple HLA-A∗0201-restricted epitopes derived from Wilms’ tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.Clin Cancer Res.2005; 11 (24 pt 1): 8799–8807.
67.
ScheibenbogenC., LetschA., ThielE.. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.Blood.2002; 100(6): 2132–2137.
68.
FujikiF., OkaY., TsuboiA.. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1∗0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-spe-cific cytotoxic T lymphocytes.J Immunother.2007; 30(3): 282–293.
69.
Pinilla-IbarzJ., MayR.J., KorontsvitT.. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.Leukemia.2006; 20(11): 2025–2033. Epub 2006 Aug 31.
70.
ElisseevaO.A., OkaY., TsuboiA.. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.Blood.2002; 99(9): 3272–3279.
71.
GaigerA., CarterL., GreinixH.. WT1-specific serum antibodies in patients with leukemia.Clin Cancer Res.2001; 7 (3 Suppl): 761s–765s.
72.
WuF., OkaY., TsuboiA.. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoi-etic malignancies.Leukemia.2005; 19(2): 268–274.
73.
KnightsA.J., ZaniouA., ReesR.C.. Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.Cancer Immunol Immunother.2002; 51(5): 271–281. Epub 2002 Apr 26.
74.
MüllerL., KnightsA., PawelecG.. Synthetic peptides derived from the Wilms’ tumor 1 protein sensitize human T lymphocytes to recognize chronic mye-logenous leukemia cells.Hematol J.2003; 4(1): 57–66.
75.
GuoY., NiiyaH., AzumaT.. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class IIrestricted manner.Blood.2005; 106(4): 1415–1418. Epub 2005 Apr 21.
76.
KobayashiH., NagatoT., AokiN.. Defining MHC class II T helper epitopes for WT1 tumor antigen.Cancer Immunol Immunother.2006; 55(7): 850–860. Epub 2005 Oct 12.
77.
MayR.J., DaoT., Pinilla-IbarzJ.. Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.Clin Cancer Res.2007; 13 (15 Pt 1): 4547–4555. Erratum in: Clin Cancer Res. 2007; 13(17): 5226.
78.
MolldremJ.J., LeeP.P., WangC.. A PR1-human leukocyte anti-gen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic mye-logenous leukemia.Cancer Res.1999; 59(11): 2675–2681.
79.
MolldremJ.J., LeeP.P., WangC.. Evidence that specific T lymphocytes may participate in the elimination of chronic mye-logenous leukemia.Nat Med.2000; 6(9): 1018–1023.
80.
RezvaniK.. PR1 vaccination in myeloid malignancies.Expert Rev Vaccines.2008; 7(7): 867–875.
81.
GreinerJ., SchmittM.. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Eur J Haematol.2008; 80(6): 461–468. Epub 2008 Feb 12
82.
SchmittM., LiL., GiannopoulosK.. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.Exp Hematol.2006; 34(12): 1709–1719.
83.
ChenJ., SchmittA., BunjesD.. The receptor for hyaluronic acidmediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.Int J Oncol.2007; 30(5): 1119–1127.
84.
SchmittM., SchmittA., RojewskiM.T.. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.Blood.2008; 111(3): 1357–1365. Epub 2007 Oct 31.
85.
GannagéM., AbelM., MichalletA.S.. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.J Immunol.2005; 174(12): 8210–8218.
86.
KesslerJ.H., BeekmanN.J., Bres-VloemansS.A.. Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.J Exp Med.2001; 193(1): 73–88.
87.
QuintarelliC., DottiG., De AngelisB.. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Blood.2008; 112(5): 1876–1885. Epub 2008 Jun 30.
88.
HanJ.F., ZhaoT.T., LiuH.L.. Identification of a new HLA-A∗0201-restricted cytotoxic T lymphocyte epitope from CML28.Cancer Immunol Immunother.2006; 55(12): 1575–1583. Epub 2006 Mar 14
89.
WuC.J., BiernackiM., KutokJ.L.. Graft-versus-leukemia target antigens in chronic mye-logenous leukemia are expressed on myeloid pro-genitor cells.Clin Cancer Res.2005; 11(12): 4504–4511.
90.
YangX.F., WuC.J., ChenL.. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Cancer Res.2002; 62(19): 5517–5522.
91.
SuemoriK., FujiwaraH., OchiT.. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A∗2402-restricted cytotoxic T lymphocytes.Cancer Sci.2008; 99(7): 1414–1419. Epub 2008 Apr 16.
92.
YanY., PhanL., YangF.. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.J Immunol.2004; 172(1): 651–660.
93.
YangX.F., WuC.J., McLaughlinS.. CML66, a broadly immuno-genic tumor antigen, elicits a humoral immune response associated with remission of chronic mye-logenous leukemia.Proc Natl Acad Sci U S A.2001; 98(13): 7492–7497.
94.
Hernández-BoludaJ.C., BellosilloB., VelaM.C.. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients.Leuk Lymphoma.2005; 46(5): 717–722.
95.
RadichJ.P., DaiH., MaoM.. Gene expression changes associated with progression and response in chronic myeloid leukemia.Proc Natl Acad Sci U S A.2006; 103(8): 2794–2799. Epub 2006 Feb 13.
96.
YongA.S., KeyvanfarK., EniafeR.. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccinebased immunotherapy.Leukemia.2008; 22(9): 1721–1727. Epub 2008 Jun 12.
97.
Pinilla-IbarzJ., CathcartK., KorontsvitT.. Vaccination of patients with chronic mye-logenous leukemia with BCRABL oncogene breakpoint fusion peptides generates specific immune responses.Blood.2000; 95(5): 1781–1787.
98.
CathcartK., Pinilla-IbarzJ., KorontsvitT.. A multivalent BCRABL fusion peptide vaccination trial in patients with chronic myeloid leukemia.Blood.2004; 103(3): 1037–1042. Epub 2003 Sep 22.
99.
BocchiaM., GentiliS., AbruzzeseE.. Effect of a p210 multipep-tide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.Lancet.2005; 365(9460): 657–662.
100.
RojasJ.M., KnightK., WangL.. Clinical evaluation of BCRABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.Leukemia.2007; 21(11): 2287–2295. Epub 2007 Jul 19.
101.
MaslakP.G., DaoT., GomezM.. A pilot vaccination trial of synthetic analog peptides derived from the BCRABL breakpoints in CML patients with minimal disease.Leukemia.2008; 22(8): 1613–1616. Epub 2008 Feb 7.
102.
DrukerB.J., GuilhotF., O'BrienS.G.. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med.2006; 355(23): 2408–2417.
103.
QazilbashM.H., WiederE., RiosR.. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia.Blood (ASH Annual Meeting Abstracts).2004; 104(11): 259. Abstract.
104.
QazilbashM.H., WiederE.D., ThallP.F.. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival.Blood (ASH Annual Meeting Abstracts).2007; 110(11): 577. Abstract.
105.
BoublikovaL., KalinovaM., RyanJ.. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.Leukemia.2006; 20(2): 254–263.
106.
CilloniD., GottardiE., MessaF.. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.J Clin Oncol.2003; 21(10): 1988–1995.
107.
OkaY., TsuboiA., TaguchiT.. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.Proc Natl Acad Sci U S A.2004; 101(38): 13885–13890. Epub 2004 Sep 13.
108.
MailänderV., ScheibenbogenC., ThielE.. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.Leukemia.2004; 18(1): 165–166.
109.
KeilholzU., LetschA., BusseA.. Clinical and immunological activity of WT1 peptide vaccination in patients with acute myeloid leukemia and myelodysplasia: results of a phase II trial.Blood (ASH Annual Meeting Abstracts).2006; 108(11): 567. Abstract.
110.
BrownA.B., KrugL.M., MaslakP.. Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms.J Clin Oncol, 2008 ASCO Ann Meet Proc (Post-Meet Ed). 2008; 26 (15S May 20 suppl): 3051. Abstract.
111.
RezvaniK., YongA.S., MielkeS.. Leukemia-associated antigenspecific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Blood.2008; 111(1): 236–242. Epub 2007 Sep 17.
112.
BorrelloI.M., SotomayorE.M.. Cancer vaccines for hematologic malignancies.Cancer Control.2002; 9(2): 138–151.
113.
LevitskyH.I., MontgomeryJ., AhmadzadehM.. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.J Immunol.1996; 156(10): 3858–3865.
114.
BorrelloI., SotomayorE.M., CookeS.. A universal granulocytemacrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.Hum Gene Ther.1999; 10(12): 1983–1991.
115.
ChiodoniC., PagliaP., StoppacciaroA.. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumorassociated antigens, and prime naive mice for a cytotoxic T lymphocyte response.J Exp Med.1999; 190(1): 125–133.
116.
DiehlL., den BoerA.T., SchoenbergerS.P.. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.Nat Med.1999; 5(7): 774–779.
117.
SotomayorE.M., BorrelloI., TubbE.. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.Nat Med.1999; 5(7): 780–787.
118.
GongJ., ChenD., KashiwabaM.. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.Nat Med.1997; 3(5): 558–561.
119.
PardollD.M.. New strategies for enhancing the immunogenicity of tumors.Curr Opin Immunol.1993; 5(5): 719–725.
120.
EngelsF.H., KoskiG.K., BedrosianI.. Calcium signaling induces acquisition of dendritic cell characteristics in chronic mye-logenous leukemia myeloid progenitor cells.Proc Natl Acad Sci U S A.1999; 96(18): 10332–10337.
121.
HeinzingerM., WallerC.F., von den BergA.. Generation of dendritic cells from patients with chronic mye-logenous leukemia.Ann Hematol.1999; 78(4): 181–186.
122.
SmitW.M., RijnbeekM., van BergenC.A.. Generation of dendritic cells expressing BCRABL from CD34-positive chronic myeloid leukemia precursor cells.Hum Immunol.1997; 53(2): 216–223.
123.
WestermannJ., KoppJ., KörnerI.. Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.Bone Marrow Transplant.2000; 25(Suppl 2): S46–S49.
124.
ChoudhuryA., GajewskiJ.L., LiangJ.C.. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic mye-logenous leukemia.Blood.1997; 89(4): 1133–1142.
125.
BoisselN., RousselotP., RaffouxE.. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.Leukemia.2004; 18(10): 1656–1661.
126.
MohtyM., JourdanE., MamiN.B.. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.Blood.2004; 103(12): 4666–4668. Epub 2004 Jan 8.
127.
SmithB., KasamonY.L., MillerC.B.. K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM).J Clin Oncol, 2006 ASCO Ann Meet Proc (Post-Meet Ed). 2006; 24 (18S June 20 suppl): 6509. Abstract.
128.
WestermannJ., KoppJ., van LessenA.. Vaccination with autol-ogous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.Br J Haematol.2007; 137(4): 297–306. Epub 2007 Apr 4.
129.
OssenkoppeleG.J., StamA.G., WestersT.M.. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells.Leukemia.2003; 17(7): 1424–1426.
130.
LiZ., QiaoY., LiuB.. Combination of imatinib mesylate with autol-ogous leukocyte-derived heat shock protein and chronic mye-logenous leukemia.Clin Cancer Res.2005; 11(12): 4460–4468.
131.
MarinD., MauroM., GoldmanJ.. Preliminary results from a phase 2 trial of AG-858, an autologous heat shock protein-peptide vaccine, in combination with imatinib in patients with chronic phase chronic myeloid leukemia (CML) resistant to prior imatinib monotherapy.Blood (ASH Annual Meeting Abstracts).2005; 106(11): 1094. Abstract.
132.
BocchiaM., AbruzzeseE., ForconiF.. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.Leukemia.2006; 20(1): 142–143.
133.
ChenC.I., MaeckerH.T., LeeP.P.. Development and dynamics of robust T-cell responses to CML under imatinib treatment.Blood.2008; 111(11): 5342–5349. Epub 2008 Mar 7.
134.
WestersT.M., JanssenJ.J., HoutenbosI.. Maintained immuno-genicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.Leukemia.2006; 20(1): 154–157.
135.
SatoN., NaritaM., TakahashiM.. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic mye-logenous leukemia.Hematol Oncol.2003; 21(2): 67–75.
136.
WangL., ButtN.M., AthertonM.G.. Dendritic cells become BCRABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.Leukemia.2004; 18(5): 1025–1027.
137.
AppelS., BoehmlerA.M., GrunebachF.. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.Blood.2004; 103(2): 538–544. Epub 2003 Sep 22.
138.
WehnerR., WendischM., SchakelK.. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.Leukemia.2006; 20(9): 1629–1632. Epub 2006 Jul 13.
139.
AppelS., RupfA., WeckM.M.. Effects of imatinib on monocytederived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.Clin Cancer Res.2005; 11(5): 1928–1940.
140.
BrauerK.M., WerthD., von SchwarzenbergK.. BCRABL activity is critical for the immunogenicity of chronic mye-logenous leukemia cells.Cancer Res.2007; 67(11): 5489–5497.
141.
BoisselN., RousselotP., RaffouxE.. Imatinib mesylate minimally affects BCRABL+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.J Leukoc Biol.2006; 79(4): 747–756. Epub 2006 Feb 3.
142.
ChenJ., SchmittA., ChenB.. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.Cancer Immunol Immunother.2007; 56(6): 849–861. Epub 2006 Sep 29.
143.
MumprechtS., MatterM., PavelicV.. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.Blood.2006; 108(10): 3406–3413. Epub 2006 Jul 27.
144.
SeggewissR., LoréK., GreinerE.. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.Blood.2005; 105(6): 2473–2479. Epub 2004 Nov 30.
145.
SinaiP., BergR.E., HaynieJ.M.. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.J Immunol.2007; 178(4): 2028–2037.
146.
ChenJ., SchmittA., GiannopoulosK.. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.Int J Oncol.2007; 31(5): 1133–1139.
147.
AswaldJ.M., LiptonJ.H., AswaldS.. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.Cytokines Cell Mol Ther.2002; 7(4): 143–149.
148.
GaoH., LeeB.N., TalpazM.. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic mye-logenous leukemia.Leukemia.2005; 19(11): 1905–1911.
149.
LederC., OrtlerS., SeggewissR.. Modulation of T-effector function by imatinib at the level of cytokine secretion.Exp Hematol.2007; 35(8): 1266–1271. Epub 2007 Jun 8.
OlavarriaE., CraddockC., DazziF.. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.Blood.2002; 99(10): 3861–3862.
152.
OlavarriaE., SiddiqueS., GriffithsM.J.. Posttransplantation ima-tinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.Blood.2007; 110(13): 4614–4617. Epub 2007 Sep 19.
153.
SavaniB.N., MonteroA., KurlanderR.. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.Bone Marrow Transplant.2005; 36(11): 1009–1015.
154.
ChenJ., SchmittA., ChenB.. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.J Cell Mol Med.2008; 12 (5B): 2107–2118. Epub 2008 Jan 11.
155.
BlakeS.J., LyonsA.B., HughesT.P.. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro.J Cell Mol Med.2008 Sep 15. [Epub ahead of print]
156.
BlakeS., HughesT.P., MayrhoferG.. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.Clin Immunol.2008; 127(3): 330–339. Epub 2008 Apr 18.
157.
BlakeS.J., Bruce LyonsA., FraserC.K.. Dasatinib suppresses in vitro natural killer cell cytotoxicity.Blood.2008; 111(8): 4415–4416.
158.
FeiF., YuY., SchmittA.. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.Exp Hematol.2008; 36(10): 1297–1308. Epub 2008 Jul 10.
159.
SchadeA.E., SchievenG.L., TownsendR.. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.Blood.2008; 111(3): 1366–1377. Epub 2007 Oct 25
160.
WeichselR., DixC., WooldridgeL.. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.Clin Cancer Res.2008; 14(8): 2484–2491.
161.
MustjokiS., LaurinolliT., EkblomM.. Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy.Blood (ASH Annual Meeting Abstracts).2007; 110(11): 2938. Abstract.
